Advertisement
Advertisement
SLS
SELLAS Life Sciences Group, Inc. Common Stock
7.47
USDSponsored
-0.39
-4.96%
Nov 16, 16:00 UTC -5
Closed
Pre-Market
26.69
+19.22
+257.32%
SELLAS Life Sciences Group, Inc. Common Stock (SLS) Earnings
SLS Earnings Reports
Positive Surprise Ratio
SLS beat 19 of 42 last estimates.
45%
Next Report
Date of Next Report
Mar 17, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.05
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
SELLAS Life Sciences Group, Inc. Common Stock earnings per share and revenue
On Nov 12, 2026, SLS reported earnings of -0.05 USD per share (EPS) for Q3 26, beating the estimate of -0.05 USD, resulting in a 0.99% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -2.12% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Enanta Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q4 26
Estimate
-$0.79
Actual
-$0.81
Surprise
-1.38%

Invivyd, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+26.47%

ALX Oncology Holdings Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-6.31%

Neumora Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.20
Actual
-$0.18
Surprise
+10.54%

Rein Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%

LeonaBio, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.73
Actual
-$0.89
Surprise
-20.35%

Jasper Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$3.02
Actual
-$13.97
Surprise
-361.93%

Dare Bioscience, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.26
Actual
-$0.18
Surprise
+32.13%

Pulmatrix, Inc. Common Stock
Report Date
Nov 17, 2026 For Q3 26
Estimate
-Actual
-$0.34
Surprise
-

CNS Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.24
Surprise
+12.85%
FAQ
What were SELLAS Life Sciences Group, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, SELLAS Life Sciences Group, Inc. Common Stock reported EPS of -$0.05, beating estimates by 0.99%, and revenue of --, -- -- expectations.
How did the market react to SELLAS Life Sciences Group, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -2.12%, changed from $8.03 before the earnings release to $7.86 the day after.
When is SELLAS Life Sciences Group, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 17, 2027.
What are the forecasts for SELLAS Life Sciences Group, Inc. Common Stock's next earnings report?
Based on --
analysts, SELLAS Life Sciences Group, Inc. Common Stock is expected to report EPS of -$0.05 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.